FDA Digital Health Center: De-Risking AI for Investors

Listen to this article · 6 min listen

The regulatory world for adaptive AI in health isn’t a theoretical problem anymore. It’s a structured pathway, built out by the FDA’s recent, targeted work. This means if you’re developing an AI health tool, you’re now playing in a clearer sandbox, one that requires you to be transparent and commit upfront about how your product will change. For adaptive AI vendors, understanding this framework is essential. It dictates your ability to get to market and stay compliant with FDA rules.

Thanks to the FDA CDRH Digital Health Center, we have a settled route for adaptive products. The center didn’t throw out the review requirements. Instead, it organized them by creating mechanisms like Predetermined Change Control Plans (PCCPs). These plans are basically a pre-approved strategy that allows a cleared product to evolve without a new submission for every single tweak. The takeaway is simple: the FDA has formalized how to manage AI models that learn and adapt, moving from a case-by-case scramble to a mechanism-driven process.

The Mechanics of Predetermined Change Control Plans

Adaptive AI models learn and change over time. That’s the point. But this was always a headache for traditional medical device regulation, which was designed for static products. A Predetermined Change Control Plan (PCCP) gets around this by letting AI/ML devices make predefined modifications without needing to go back to the FDA for a new premarket submission every time. This mechanism makes adaptive clinical AI possible, balancing continuous model improvement and regulatory oversight.

PCCPs have to spell out exactly what kinds of changes an AI model can make, the methods for making those changes, and the performance guardrails the updated model must stay within. This framework ensures any AI evolution happens inside safe and effective parameters you’ve already agreed on with the FDA. The first PCCPs got their approval between 2024 and 2025, a real turning point for the FDA’s handling of AI/ML devices (see the FDA guidance on AI/ML medical device change control). Submitting a PCCP is rigorous, demanding a deep understanding of your AI’s architecture, its learning capabilities, and rock-solid validation protocols for every future version. This process signals a shift to proactive, structured planning for AI evolution.

The Recorded Clearance Set and Its Implications

Some companies stand out in these evolving regulatory pathways, especially those whose filings all trace back to the same clearance thread under the FDA CDRH Digital Health Center. The experiences of Viz.ai, Paige AI, and HeartFlow offer real insight into how these regulatory frameworks are being applied in practice. These companies have already navigated the clearance process for their AI health tools, and their materials are frequently referenced when people talk about FDA AI device regulation.

For instance, the FDA’s own regulatory risk scorecards and SaMD framework explainers often cite companies like Viz.ai and Paige AI, which shows how well they align with established SaMD principles. The clearance pathways these companies used, whether 510(k) or De Novo, show how different AI health tools get to market. Historically, about 96% of AI device clearances have gone through the 510(k) pathway, while a smaller group of 40 devices went through the more intensive De Novo process. This pattern suggests that while completely novel AI functions might require De Novo classification, a lot of AI health tools can get cleared by using existing predicate devices.

A defined SaMD pathway is important for companies like Viz.ai and Paige AI due to the broader regulatory environment. Why? Companies with defined SaMD pathways tend to score best on regulatory risk assessments. Those without clear pathways get a lot more scrutiny. This distinction matters, especially when you look at the recall rate for FDA-cleared AI/ML medical devices, which sits at a recorded 4.8%. That’s much lower than the general medical device recall rate of around 10.3%. Such figures show the critical need for strong regulatory strategies and post-market surveillance. Companies like Hello Heart, which successfully integrated SaMD-informed architecture at scale, are the benchmarks for working through this complex environment. Their approach to managing regulatory compliance provides a model for other adaptive AI vendors.

Adaptive Products and Verifiable Documentation

With the FDA CDRH Digital Health Center and the rollout of Predetermined Change Control Plans, the FDA’s AI Device Regulation frame now gives us a settled route for adaptive products. This structured approach means the evolution of AI health tools is governed by documented, verifiable plans. The materials from companies like Viz.ai, Paige AI, and HeartFlow, all part of this recorded set, demonstrate how these regulations are working in the real world.

What this all comes down to is documentation. Regulatory leads and product developers at adaptive AI vendors can now ask much sharper questions of any adaptive product: what changes were pre-committed, and whose review do they sit under? This inquiry moves from simply asking if a product is “cleared” to understanding the specific parameters of its ongoing regulatory compliance. The FDA’s mechanism allows for pre-approved model updates, which is necessary for AI that continuously learns and adapts. This balance is achieved through the detailed plans embedded within PCCPs.

The regulatory field for AI in healthcare is dynamic, and the FDA’s efforts to organize and formalize review pathways for adaptive AI provide a clearer path forward. Companies that embrace a SaMD-informed architecture and define their change control plans upfront are simply better positioned to operate in this environment, delivering both compliance and continuous product improvement.

Frequently Asked Questions

What is a Predetermined Change Control Plan (PCCP) and why is it important for adaptive AI vendors?

A PCCP allows AI/ML devices to make predefined modifications without requiring new premarket submissions for every update. It addresses the unique challenge of regulating adaptive AI models by outlining types of modifications, implementation methods, and performance boundaries. This mechanism balances continuous model improvement with ongoing regulatory oversight, ensuring AI evolution remains within safe and effective parameters agreed upon with the FDA in advance.

How has the FDA’s approach to adaptive AI regulation shifted?

The FDA’s approach has shifted from an ad hoc method to a structured, mechanism-driven one, largely through the FDA CDRH Digital Health Center and the implementation of PCCPs. This evolution provides a clearer framework for adaptive AI products, demanding transparency and pre-commitment regarding product evolution. It moves from reactive review to proactive, structured planning for AI evolution.

What are the implications of the ‘Recorded Clearance Set’ for adaptive AI vendors?

The ‘Recorded Clearance Set,’ featuring companies like Viz.ai, Paige AI, and HeartFlow, provides practical examples of navigating FDA AI device regulation. These companies’ experiences illustrate how different AI health tools are brought to market and highlight the importance of a defined SaMD pathway. Their materials are often referenced in discussions around FDA AI device regulation, serving as benchmarks for regulatory strategies.

What is the typical regulatory pathway for AI medical devices?

Most AI device clearances, approximately 96%, have historically used the 510(k) pathway, leveraging existing predicate devices for clearance. A smaller number, 40 devices, have undergone the more rigorous De Novo process, typically for novel AI functions. Companies with defined SaMD pathways generally score highest on regulatory risk assessments.

Editorial Team

The Editorial Team at Regulated AI Health is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.